# Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

Study · id `cardio:ct-nct06449235` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06449235](<https://clinicaltrials.gov/study/NCT06449235>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06449235

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 938 participants.

## Technical summary

Registry record NCT06449235. Non-randomized; no masking; primary purpose treatment. Start 2024-09 (anticipated); primary completion 2025-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 938 participants (planned count; ClinicalTrials.gov record NCT06449235, source copy `cardio:ctgov-nct06449235-2024-07-16`, retrieved 2026-10-26)
- Planned start: 2024-09 (anticipated) (ClinicalTrials.gov record NCT06449235, source copy `cardio:ctgov-nct06449235-2024-07-16`, retrieved 2026-10-26)
- Primary completion: 2025-04 (anticipated) (ClinicalTrials.gov record NCT06449235, source copy `cardio:ctgov-nct06449235-2024-07-16`, retrieved 2026-10-26)
- Completion: 2025-06 (anticipated) (ClinicalTrials.gov record NCT06449235, source copy `cardio:ctgov-nct06449235-2024-07-16`, retrieved 2026-10-26)
- Countries: Bangladesh (ClinicalTrials.gov record NCT06449235, source copy `cardio:ctgov-nct06449235-2024-07-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06449235-2024-07-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh
- Condition: Type2diabetes
- Intervention (Drug): Omarigliptin
- Intervention (Drug): Sulphonylureas
- Intervention (Drug): Metformin
- Intervention (Drug): Other DPP4-i
- Intervention (Drug): Thiazolidinediones
- Intervention (Drug): Alpha-Glucosidase Inhibitor
- Intervention (Drug): Glucagon-Like Peptide-1
- Intervention (Drug): Receptor Agonists (GLP1RA)
- Intervention (Drug): SGLT2 inhibitors
- Lead sponsor: Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
- Lead sponsor class: OTHER
- Collaborator: Pi Research and Development Center
- Collaborator class: UNKNOWN
- Collaborator: Acme Laboratories Ltd.
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 8fc6286e7fa0257112bfc46d700be1d22f46a48ebc100972c06e93f78e1c7c6a
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
